47
Participants
Start Date
March 12, 2019
Primary Completion Date
August 3, 2020
Study Completion Date
August 31, 2020
Paltusotine
Paltusotine, capsules, once daily by mouth
Allegheny Endocrinology Associates, Pittsburgh
University of Michigan, Ann Arbor
Northwestern University Feinberg School of Medicine, Chicago
UCLA Gonda Diabetes Center, Los Angeles
OHSU Northwest Pituitary Center, Portland
Massachusetts General Hospital, Boston
CETI - Centro de Estudos em Terapias Inovadoras, Curitiba
Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ) Centro de Pesquisa em Neuroendocrinologia, Rio de Janeiro
CPQuali Pesquisa Clinica, São Paulo
LMU Clinic of University of Munich, Munich
"General Hospital of Athens Evangelismos", Athens
"General Hospital of Athens Gennimatas", Athens
"General Hospital of Athens Laiko", Athens
"General Hospital of Athens Ippokratio", Thessaloniki
Military Health Center, Division of Endocrinology, Budapest
Semmelweis University Faculty of Medicine, Budapest
University of Pécs Medical School, Pécs
Azienda Ospedaliera Universitaria Federico II, Napoli
Waitemata District Health Board, North Shore Hospital, Takapuna
Endocrine, Diabetes and Research Centre, Wellington Hospital, Wellington
Clinic of Endocrinology Independent Public Health Care Centre University Hospital in Kracow, Krakow
"National Institute of Endocrinology C. I. Parhon", Bucharest
Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade
University Hospital Bratislava, Bratislava
University Hospitals Coventry and Warwickshire NHS Trust, Coventry
Leeds Teaching Hospitals NHS Trust, Leeds
Lead Sponsor
Crinetics Pharmaceuticals Inc.
INDUSTRY